News

How AI Will Make Our Lives Better (And Worse)

May 31, 2023・By David H. Freedman・Newsweek Magazine The explosion of progress in artificial intelligence in recent months has surprised even...

News

AI-discovered drug shows ‘enormous potential’ to treat schizophrenia: ‘Real need for better treatment’

May 9, 2023・By Angelica Stabile・Fox News PsychoGenics CEO reveals how machine learning has enabled new steps toward addressing mental disorder As...

News

PsychoGenics Launches eCube, a New AI-Enabled Platform for Drug Discovery

April 6, 2023・Businesswire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and preclinical CRO...

News

PsychoGenics highlights a long-term collaboration with the TSC Alliance on Rare Disease Day

Feb. 28, 2023 On this Rare Disease Day, we want to highlight and honor our long-term collaboration with the TSC...

News

PsychoGenics CEO explores CNS drug development trends

February 4, 2023 · By Brian Buntz · Drug Discovery & Development In the late 2000s, many companies, particularly Big...

News

Why the TAAR1 agonist ulotaront holds promise for schizophrenia

November 22, 2022 · By Brian Buntz · Drug Discovery & Development Ulotaront (SEP-363856), a trace amine-associated receptor 1 (TAAR1)...

News

A novel phenotypic approach to CNS drug discovery

November 10, 2022 · Drug Discovery World The newest addition to the free DDW podcast is the In Conversation With series, where...

News

4 next-gen CNS drug development trends

By Brian Buntz · October 24, 2022 · Drug Discovery & Development The past couple of years have had a significant...

News

Why Psychogenics and Emyria are collaborating to examine MDMA-inspired compounds

By Brian Buntz · Oct 12, 2022 · Drug Discovery & Development CNS-focused contract research organization PsychoGenics has forged a collaboration with clinical-stage...

News

PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics

Oct 11, 2022 · Business Wire PARAMUS, N.J.–(BUSINESS WIRE)–PsychoGenics Inc. (“PsychoGenics” or the “Company”), a leader in AI-enabled phenotypic drug discovery and...

Partner with us and transform your program

DISCOVER YOUR NEXT BREAKTHROUGH WITH PSYCHOGENICS

Get Started